Chronic rhinitis solution NEUROMARK secures €62.5 million as Irish startup Neurent Medical closes Series C

February 12, 2026 at 10:21 AM UTC
EU-Startups
Original: EN
Chronic rhinitis solution NEUROMARK secures €62.5 million as Irish startup Neurent Medical closes Series C

Neurent Medical, an Irish startup focused on medical technology, has successfully closed a €62.5 million Series C funding round. This significant investment, led by MVM Partners and Sofinnova Partners, will be instrumental in driving the commercial expansion of their NEUROMARK solution for chronic rhinitis. The funding underscores growing investor confidence in European HealthTech and MedTech ventures aiming to provide innovative treatments for prevalent health conditions. The NEUROMARK System utilizes proprietary Impedance Controlled Radiofrequency technology to address hyperactive posterior nasal nerves, a root cause of chronic rhinitis symptoms. This minimally invasive approach aims to offer durable relief with minimal downtime and a strong safety profile. This development aligns with a broader trend in Europe, where several HealthTech startups are securing substantial capital to advance AI-driven platforms and novel medical devices, signaling a robust ecosystem for digital health innovation. This substantial funding positions Neurent Medical at the forefront of European MedTech fundraising for the 2025-2026 period. The investment will fuel not only commercial growth but also efforts to broaden clinical evidence and enhance their product pipeline. Such advancements are crucial for establishing European digital health solutions as competitive alternatives within the global market, fostering digital sovereignty in a vital sector.

Curated and translated by Europe Digital for our multilingual European audience.

Source Information

Publication: EU-Startups
Published: February 12, 2026 at 10:21 AM UTC
All rights remain with the original publisher.